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Multidrug resistant bacteria are a serious worldwide problem, especially carbapenem-
resistant Enterobacteriaceae (such as Klebsiella pneumoniae and Escherichia coli),
Acinetobacter baumannii and Pseudomonas aeruginosa. Since the emergence of
extensive and pan-drug resistant bacteria there are few antibiotics left to treat patients,
thus novel RNA-based strategies are being considered. Here, we examine the current
situation of different non-coding RNAs found in bacteria as well as their function and
potential application as antimicrobial agents. Furthermore, we discuss the factors that
may contribute in the efficient development of RNA-based drugs, the limitations for their
implementation and the use of nanocarriers for delivery.
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INTRODUCTION
In the year 2014, the World Health Organization reported the critical problem of antibiotic resistant
bacteria (World Health Organization [WHO], 2014). The global resistance levels of bacterial
isolates have climbed unrelentingly in the last decades regardless of their source, i.e., clinical
settings, in-patients, community, food-related or environmental niches. This led to the increase in
the overall morbidity and mortality due to multidrug resistant bacteria (MDR) infections (Baquero
et al., 2015; Woolhouse et al., 2016). Throughout the years, misused and abused antimicrobial drugs
have led to the selection of resistant strains difficult to eradicate (Baquero et al., 2015). As a result,
bacteria have evolved into extensive- (XDR) or pan-drug resistant (PDR) phenotypes.
The Center for Disease Control and Prevention has classified some gram-negative bacteria
as urgent or serious threats for public health. Among them, Enterobacteriaceae resistant
to carbapenems (CRE) or to extended spectrum beta-lactamases (EBSL), multidrug resistant
Acinetobacter and Pseudomonas species present serious hazards. The lack of novel antimicrobial
drugs available in the market or the drug development pipeline to combat these pathogens, the
high cost of discovering and developing new compounds and the fast evolution of bacterial
population to resistant phenotypes are particularly worrisome. Therefore, novel approaches to
battle these pathogens are currently encouraged (World Health Organization [WHO], 2014). One
promising strategy is the use of RNA-based therapies. This review examines the current situation
of non-coding RNA (ncRNA) elements as antimicrobial agents and discusses some strategies and
limitations for their implementation.
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NON-CODING RNAs AS THERAPEUTICS
AGENTS
Since a few decades ago, RNA molecules have been foreseen as
potential drugs against pathogens. With the characterization of
novel ncRNAs in bacteria, this strategy seems more plausible.
Among the ncRNA molecules studied for their therapeutic
potential are the ribozymes hammerhead, group II introns,
glmS, and RNAse P (Figure 1) (Cui and Davis, 2007; Ferré-
D’Amaré, 2010; Lambowitz and Zimmerly, 2011; Hammann
et al., 2012; Altman, 2014; Khan et al., 2016). One of
the most studied ribozymes is RNAse P. Its activity and
interaction with external guide sequence as therapeutics against
MDR bacteria has been extensively reviewed elsewhere, and
interesting advances in the field have been reported (Forster and
Altman, 1990; Kirsebom and Svärd, 1992; Svärd and Kirsebom,
1993; Altman, 2014; Davies-Sala et al., 2015). The approach
for the use of this ribozyme is based on the delivery of
nuclease-resistant analogs, such as locked nucleic acids/DNA co-
oligomers or phosphorodiamidate morpholino oligonucleotide
EGSs conjugated to permeabilizer peptide (PPMO), that induce
a RNAse P-mediated degradation of the target mRNA once
introduced in the host. Further advances using this strategy will
most likely provide interesting results that will contribute in
developing novel RNA-based drugs.
Hammerhead ribozymes have been used to develop antiviral
compounds; however, their use against bacteria has not been
considered yet (Hammann et al., 2012). Group II introns are
self-splicing elements that in the presence of its cofactor can
retrotranspose to novel target sites within a genome (Lambowitz
and Zimmerly, 2011). Several attempts were made to use these
ribozymes as vehicles for the delivery of cargo genes to inhibit
cell growth or promote cell death (Plante and Cousineau,
2006; Mohr et al., 2013). One particular subclass of group II
introns, C-attC, has the peculiar ability to insert downstream
of DNA secondary structures adjacent to antimicrobial gene
cassettes located in integron platforms (Centrón and Roy, 2002;
Quiroga et al., 2008). The ability exhibited by C-attC group
II introns to selectively insert within gene cassettes suggests
that they could be employed as vectors to deliver genetic
material at specific target sites. Last, the glmS ribozyme has
also been a subject of study as an antimicrobial drug. It has
been reported that in the presence of carba-α-D-glucosamine
it can promote mRNA degradation and inhibit cell growth
(Ferré-D’Amaré, 2010; Schüller et al., 2017). Although all these
RNA elements have promising features that could be adapted
to engineer RNA based drugs, further advances in their delivery
are necessary.
The recent upsurge of other functional ncRNAs in bacteria
have revealed their essential role in the regulation of different
processes, such as cell physiology, defense, horizontal gene
transfer, virulence, etc (Gottesman and Storz, 2011; Storz et al.,
2011; Caldelari et al., 2013; Fröhlich and Papenfort, 2016).
Since many ncRNAs are key regulatory elements, they are
currently considered for designing novel therapeutic strategies.
These RNAs are commonly small in size (<500 nt), and can
either act in cis of the target messenger RNA (thermoregulators,
riboswitches) or in trans [small RNAs, antisense RNAs, clustered
regularly interspaced short palindromic repeats (CRISPRs)]
(Figure 1). Riboswitches and thermoregulators control the
expression of an adjacent mRNA upon sensing physical or
chemical signals (Winkler et al., 2002; Chowdhury et al., 2006).
The environmental effect or the presence of specific molecules
lead to structural modifications in the 5′-UTR of a target
mRNA that can either release or sequester the ribosome binding
site, resulting in the activation or repression of translation.
While thermoregulators are mostly temperature-sensitive RNAs
that respond to heat or cold shock, riboswitches are more
complex elements that regulate a wide variety of genes. Some
riboswitches, such as the guanine riboswitch, have shown
promising results as targets for novel antimicrobial compounds
against the pathogen Clostridioides difficile (Yan et al., 2018).
Also, it can regulate the expression of aminoglycoside antibiotic-
resistance genes (Jia et al., 2013; Rekand and Brenk, 2017).
Mechanistic insight into these RNA sensors and their use
as antimicrobials can be found in comprehensive reviews
(Chowdhury et al., 2006; Rekand and Brenk, 2017). Two
additional ncRNA elements, sRNA and CRISPRs, have lately
drawn more attention as potential RNA-based antimicrobial
drugs. In the following sections, we will focus on their use,
strength and limitations.
SMALL NON-CODING RNAs IN
BACTERIA
Small non-coding RNAs (sRNA) are short RNAs that regulate
post-transcriptionally gene expression. These RNAs can be
encoded in the opposite strand of the target mRNA (known
as antisense or cis sRNA), or encoded in trans to the target
mRNA. The trans acting sRNA, or simply sRNAs, are RNA
regulators frequently found in bacteria that interact by imperfect
base pairing with its target mRNA. Their regulation process
usually involves the chaperon protein Hfq, as well as ProQ and
CsrA (Wagner and Romby, 2015; Olejniczak and Storz, 2017),
albeit interactions with other chaperons and cis sRNAs have also
been reported (Opdyke et al., 2004; Ross et al., 2013; Ellis et al.,
2015). These proteins participate in the sRNA and its target
mRNA interaction, in mRNA translation or during RNA decay.
As a result, sRNAs can repress translation by binding to the
initiation target site, by sequestration of the ribosome standby
site, or by facilitating mRNA degradation with ribonucleases; they
can also activate translation by exposing a sequestered ribosome
binding site or protecting a mRNA by masking a ribonuclease
cleavage site (Gottesman and Storz, 2011; Storz et al., 2011;
Caldelari et al., 2013).
Several studies have shown that sRNAs regulate a wide
variety of genes that code for proteins involved in processes
related to physiology, metabolism, stress responses or quorum
sensing (reviewed in Gottesman and Storz, 2011; Storz et al.,
2011; Caldelari et al., 2013; Fröhlich and Papenfort, 2016).
Many of them are capable of regulating more than one target
mRNA, which unveils a complex sRNA-based network (Storz
et al., 2011). Furthermore, recent studies have suggested that
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FIGURE 1 | Schematic representation of the current scenario of RNA-based therapies. The blue box shows the outline of candidate antimicrobial ncRNA elements;
in the red box are illustrated some key aspects to be considered for RNA drug design and development. Yellow spheres depict gold nanoparticles and gray spheres
represent polymeric nanoparticles.
approximately half of the mRNAs are regulated by sRNAs
(Hör and Vogel, 2017), which showcase their important role in
post-transcriptional control. sRNAs regulators provide different
benefits to the host, such as reduced metabolic cost and a
tighter and faster gene regulation, that help bacteria to adapt
to new environments (Beisel and Storz, 2010). Thus, sRNA-
mediated regulation is currently regarded as RNA-based drug
targets. In this regard, Na et al. (2013) designed several synthetic
sRNAs targeting various mRNAs RBS, which modulate gene
expression in different Escherichia coli strains. Since then,
several studies on the application of sRNAs in metabolic
engineering and synthetic biology have been published (reviewed
in Villa et al., 2019).
Other appealing target candidates include virulence and
resistance genes as well as mobile elements, thus they have
become appealing candidates. In this regard, it has been reported
that some sRNAs are involved in antibiotic uptake (GcvB, RyhB,
MicF, ErsA), drug efflux (DsrA RydC, SdsR, NrrF), biofilm
formation (RprA OmrA/B, McaS, RybB, RydC), and modification
of lipopolysaccharide and cell wall synthesis (MgrR, MicA,
Sr006). While most of these sRNAs have been extensively studied
in E. coli and Salmonella strains (reviewed in Dersch et al.,
2017), there is scarce information about their activity in other
bacteria. The identification of sRNAs related to antimicrobial
resistance genes and their mechanisms of dissemination exposes
a new strategy for the delivery of synthetic sRNAs to XDR
and PDR bacteria.
THE CRISPR-Cas SYSTEMS IN
BACTERIA
CRISPR-Cas systems are part of the immune system of bacteria
and provide protection against mobile genetic elements. Its
immunity is based on the specific sequence recognition of foreign
DNA or RNA by base pairing with short guide RNAs (32–35
nt), followed by the cleavage of the target sequence by CRISPR-
associated protein (encoded by the cas genes). There are two
classes and several types of CRISPR-Cas systems, which are
usually composed of a cas operon adjacent to a CRISPR array
(Koonin et al., 2017). Such array consists of direct repeats
interspaced by the DNA invader-derived guide sequences that
anneals with the exogenous material (Jackson et al., 2017;
Hille et al., 2018 and references within). In recent years, the
CRISPR-Cas machinery has been repurposed for gene editing
and interference. These systems have a highly sequence-specific
targeting ability that inspired the research community to use
them as novel antimicrobial agents. The unique activity of
CRISPR-Cas systems regards them as elements that can either
attack resistance genes or populations of unwanted pathogenic
bacteria, while preventing the eradication of bacteria that might
be beneficial (Bikard and Barrangou, 2017; Goren et al., 2017;
Greene, 2018).
To date, a few CRISPR guide RNAs have been designed to
target virulence factors, antimicrobials determinants or essential
chromosomal genes from specific pathogens, such as E. coli
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or Staphylococcus aureus (Bikard et al., 2014; Citorik et al.,
2014; Gomaa et al., 2014). These systems were employed to
efficiently target a particular DNA sequence resulting in the
introduction of chromosome deletions in different pathogens,
which consequently led to cell death or to the reduction in the
population of unwanted bacteria (Vercoe et al., 2013; Bikard et al.,
2014; Citorik et al., 2014; Gomaa et al., 2014; Hampton et al.,
2016). Vercoe et al. (2013) observed that a guide or CRISPR RNA
(crRNA) programmed to target a large horizontally acquired
island in Pectobacterium atrosepticum activated the endogenous
CRISPR-Cas system and promoted the loss of both islands and
the accessory genes encoded within. Moreover, double-stranded
DNA breaks caused by the Cas machinery made CRISPR-Cas
target the bacterial chromosome and resulted in the inhibition
of cell growth and a filamentation phenotype (Vercoe et al.,
2013). Although it has been confirmed that resistance genes
can be eliminated using this technique (Bikard et al., 2014;
Citorik et al., 2014), spontaneous point mutations in bacterial
genomes might affect the action of synthetic guide CRISPR
RNAs or endogenous CRISPR-Cas systems. Therefore measures
to counteract these effects during new drug development
should be contemplated.
CONSIDERATIONS ON THE DESIGN OF
RNA-BASED ANTIMICROBIAL
STRATEGIES
The development of RNA-based antimicrobial strategies requires
the understanding of the factors involved in the mechanisms
and activities of each RNA element, the determination of their
specificity to ascertain that no off-targets and unexpected events
occur, and the evaluation of the impact that introducing these
RNAs may cause to the host. Most studies have been limited
to reference strains, such as E. coli MG1655, whereas only few
of them have been done using clinical isolates (Bikard et al.,
2014; Citorik et al., 2014; Gomaa et al., 2014; Chan et al.,
2017; Dersch et al., 2017). The extensive genome sequencing
projects in antimicrobial resistant pathogens revealed that clinical
isolates have large, versatile and plastic genomes that encode an
assortment of cellular factors. The process of selecting a target
mRNA and designing RNA-based drugs, either using sRNAs
or CRISPR guide RNAs, will most likely require a subsequent
validation in different bacteria (Figure 1).
A special consideration should be placed on the selection of
the target mRNAs (Figure 1). Most mRNAs are good candidates
for RNA-based antimicrobials; however, current approaches for
developing drugs are aiming for specific targets that have little or
no effect on the host microbiota (Langdon et al., 2016; Lichtman
et al., 2016). To overcome this problem, a safe approach involves
directing the attack to specific genes that will only have an impact
on pathogenic bacteria. Therefore, virulence genes, antimicrobial
resistant determinants, mobile genetic elements or genes involved
in horizontal transfer are ideal candidates. Designing sRNAs or
guide RNAs that hybridize specifically with those genes will limit
the effect on microbial flora even if they are introduced in other
host cells.
Furthermore, the design of synthetic RNAs should take into
consideration their stability in the cell, as well as their folding into
proper structures (Figure 1). Previous studies have shown that
single strand RNAs are more stable when their extremities are
protected by stem-loop structures, which improves their survival
in the cell (Majdalani et al., 1998). Although this increases
their stability, they are not exempted of the effects of the host
degradation machinery. In this regard, RNAs that bind to specific
proteins (e.g., Hfq or Cas) can be protected from the action
of RNAses, which will increase RNA survival in the cell and
the execution of the desired tasks. Therefore, functional and
structural studies on Hfq interaction with synthetic sRNAs or
between guide RNAs and Cas proteins will help to optimize their
activity and reduce undesired degradation.
Despite the fact that chaperons and cofactors can provide
stability to the candidate RNAs, delivery of RNPs may prove
difficult in bacterial cells. Alternatively, some studies have
suggested the use of endogenous CRISPR-Cas systems against
XDR and PDR bacteria. A caveat in this strategy is that CRISPR-
Cas systems are not conserved in bacterial species (Koonin et al.,
2017) and previous confirmation of their presence in the host will
be necessary.
RNA DELIVERY IN BACTERIA
The need to explore new delivery systems capable of overcoming
the challenges of specificity, selectivity for targeting and efficiency
has appeared. Transport of genetic material from an extracellular
environment into cytosolic compartment is a complex task
specially when referred to transport across bacteria barriers,
outer membrane (in gram-negative bacteria), the cell wall and
the cytoplasmic membrane (Chen and Dubnau, 2004). Synthetic
nanocarriers and bioinspired vehicles, such as bacteriophages,
have been investigated for their use in drug and gene delivery
systems (Figure 1). Bacteriophages are viruses with a highly
efficient ability for compressing and wrapping DNA to form
compact particles of 28 nm (MS2), 200 nm (T4) or 890 nm
(M13) (Karimi et al., 2016). Based on the potential of these
viruses to naturally act as carriers, they have been employed
in the transfer of genetic information. Phage therapy has
been revisited as an alternative to antibiotics for treating
bacterial infections in different models as well as implemented
in phase I and II of clinical trials (reviewed in Lin et al.,
2017). Non-lytic bacterial cellular death was reported employing
phagemid constructs that can carry different antimicrobial
compounds and target specific bacteria (Krom et al., 2015).
The authors showed that this approach led to a significant
reduction in bacterial cell viability in vitro and an 80%
survival rate in a murine peritonitis infection model, which are
promising results.
Toward ncRNA-based antimicrobial therapeutics, Na et al.
(2013) showed that custom sRNA cassettes carrying the antisense
sequence of a target mRNA and an Hfq-binding motif it is
possible to modulate gene expression in different E. coli strains.
Based on these findings Bernheim et al. (2016) developed a
protocol for synthetic sRNA delivery in E. coli cells using a
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phagemid construct and a non-lytic M13 phage that upon
encapsulation can infect a population.
On the other hand, three research groups have assessed the
delivery of CRISPR-Cas system using phage particles as vectors
that seizes the specificity of phages for their hosts (Bikard et al.,
2014; Citorik et al., 2014; Yosef et al., 2015). Citorik et al. (2014)
used CRISPR-Cas technology and created RNA-guided nucleases
targeting antibiotic resistance and virulence determinants in
carbapenem-resistant Enterobacteriaceae and enterohemorragic
E. coli. This strategy involved the delivery of RNA-guided
nucleases using a bacteriophage or a conjugative plasmid. Bikard
et al. (2014) used a phage-encoded CRISPR-Cas9 to target
antibiotic resistance genes in strains of Staphylococcus aureus.
Both groups confirmed their results with in vivo experiments,
in a Galleria mellonella infection model and a mouse skin
colonization model (Bikard et al., 2014; Citorik et al., 2014).
Lastly, Yosef et al. (2015) improved the delivery model by
combining the use of a λ prophage and the lytic phage T7.
They used E. coli as a host and delivered the CRISPR cascade
genes and cas3 of a type I-E CRISPR-Cas system along with the
guide crRNAs designed to target the beta-lactam resistance genes
blaNDM−1 and blaCTX−M−15. They proposed to sensitize E. coli
cells to β-lactam antibiotics while simultaneously conferring a
selective advantage to sensitized bacteria by protecting them from
lytic phages with an engineered CRISPR-Cas system delivered by
a λ prophage. Therefore, when E. coli cells were infected with a
T7 phage, only bacteria that were sensitized and had an active
CRISPR-Cas system were able to resist the infection. The authors
stated that the use of this technology would reduce multi-drug
resistant populations, overcome the resistance problem and re-
purpose several antibiotics that are no longer used. However,
some limitations regarding conjugation efficiency, host range and
phage resistance suggest that new delivery vehicles need to be
tested. In this regard, nanotechnology offers promising options
of nanocarriers that should be explored for antimicrobial delivery
systems, a wide variety of materials, and the possibility to improve
targeting designed to specifically reach bacterial cells. Of note,
extracellular vesicles (EVs) derived from phage-sensitive bacteria
have also been proposed as potential extra opportunities in phage
therapy. EVs can be administered prior to the phages to enhance
the targeting of bacteria and even enable the infection of novel
bacterial host targets (Liu et al., 2018).
Non-viral nanoparticles have been tested as nanocarriers to
achieve the incorporation of genetic material in bacteria. For
instance, encapsulation of plasmid DNA with different molecular
weights of chitosan (chitosan-pDNA NPs) resulted in different
NP sizes (457 to 820 nm) that greatly enhanced transformation
efficiency in E. coli cells compared to naked DNA (Bozkir and
Saka, 2004). Further showing the potentiality of nanoparticles
and chitosan to introduce genetic material in bacterial cells,
other research groups have evaluated the efficiency of plasmid
DNA delivery using electrospray of chitosan-pDNA NPs into
non-competent vs. competent E. coli (Abyadeh et al., 2017),
electrospray of gold NPs (GNPs) in non-competent E. coli (Lee
et al., 2011), and transformation of GNPs – pDNA conjugates
by high temperature and friction forces of the Yoshida effect in
gram positive and gram negative bacteria (Kumari et al., 2017).
However, to the best of our knowledge they have not been tested
yet using ncRNAs as cargo.
Although the progress in the field is promising, there are
still many questions to be answered. For instance, which
nanoparticle will efficiently deliver sRNAs without compromising
its activity? How functional and adaptable has to be a synthetic
system in order to battle the evolution of bacteria toward
antimicrobial resistance?
And in the particular case of CRISPR-Cas systems, is it
suitable to use the endogenous machinery of pathogens and
deliver only CRISPR RNAs, or is it better to deliver the entire
CRISPR-Cas machinery? Which type of CRISPR-Cas is more
efficient? How efficient is the delivery of these systems with
bacteriophages? In this regard, it is well-known that bacteria can
resist phage infections using other strategies besides CRISPR-Cas,
i.e., by spontaneous mutations of sensitive cells independently
of the action of the virus, with restriction and modification
systems, masking of membrane receptors or with toxin/antitoxin
systems. Moreover, recent reports have revealed that bacteria can
encode anti-CRISPR proteins in prophages, which could affect
the efficiency of the CRISPR-Cas system (Labrie et al., 2010;
Seed, 2015; van Houte et al., 2016; Borges et al., 2017; Oechslin,
2018; Pawluk et al., 2018). There are no studies yet on how these
mechanisms would work in face of these therapies.
CONCLUDING REMARKS
The antimicrobial resistance problem is a crucial global issue that
needs to be addressed. The development of alternative strategies
to battle bacterial pathogens are of outmost importance. RNA-
based therapies, such as synthetic sRNAs or CRISPR guide
RNAs, are attractive strategies to tackle this problem. Both
approaches can target accessory genome of pathogenic bacteria,
in particular extended spectrum beta-lactams, carbapenems or
colistin resistance genes. However, it is important to develop
systems that not only are successful for delivering highly
effective RNA elements but that can also be rapidly modified
upon bacterial acquisition of novel resistances and limits the
selection of MDR bacteria. Furthermore, a combined system
targeting several mRNAs in a coordinate manner would ideally
be more robust. In this regard, the CRISPR-Cas systems have
revolutionized the world of microbiology, and their use in the
fight against antibiotic multiresistance is going to be without a
doubt a powerful tool. Notwithstanding, more studies are indeed
necessary to be able to deliver these RNAs with high specificity
and achieve a clinically relevant efficacy. The advances on the
activity of sRNA and CRISPR-Cas systems have raised the issue of
their use as antimicrobial drugs, further progress in the RNA and
nanotechnology field are necessary to answer all these questions.
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